Redmond, United States
SystImmune, founded in 2014 and based in Redmond, WA, is a promising player in the bio-pharmaceutical sector, specifically targeting cancer treatment. They are at the forefront of developing innovative therapeutic solutions such as bi-specific and tri-specific antibodies, alongside antibody-drug conjugates (ADC's), aiming for systematic interventions in the solid tumor micro-environment.
The company leverages its team of highly experienced immuno-oncology scientists and several technology platforms to create advanced antibody-based drug therapies. While the company's slogan is not available, its mission is clearly focused on direct tumor attack and immune system activation to combat cancer effectively.
Despite lacking specific recent investment records, SystImmune represents a unique proposition for investors seeking to back cutting-edge cancer treatment solutions. Investors interested in the bio-pharmaceutical domain may find potential in SystImmune's commitment to pioneering biologics.
